Ref: UKHSA publications gateway number GOV-11094PDF, 285 KB, 23 pages
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a
version of this document in a more accessible format, please email firstname.lastname@example.org.
Please tell us what format you need. It will help us if you say what assistive technology you use.
All babies born on or after 1 August 2017 are eligible for the hexavalent vaccine, which includes hepatitis B (HepB), for their primary immunisations.
In 2022, the UK Health Security Agency (UKHSA) will supply Vaxelis® in addition to Infanrix hexa® for use in the primary immunisation schedule.
This document provides information about the 2 hexavalent vaccines for healthcare practitioners who are involved in delivering or advising on the infant primary vaccination programme. Although originally published as 2 separate documents in 2017 (routine programme guidance and selective programme guidance) this updated version combines these 2 documents.